| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 208,458 | 136,029 |
| Proceeds from employee stock purchase plan | 933 | 1,013 |
| Proceeds from stock option exercises | 6,826 | 468 |
| Net cash provided by financing activities | 7,759 | 1,481 |
| Net decrease cash, cash equivalents and restricted cash | -37,275 | -45,447 |
| Cash and cash equivalents at beginning of period | 154,300 | - |
| Cash and cash equivalents at end of period | 117,025 | - |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)